is a matter of concern as these patients require specific follow-up to prevent life-threatening complications.
Here, we analyzed the nineteen known albinism genes in a series of 990 index patients. This allowed us to have a wide panorama of molecular alterations in patients with albinism.
| RESULTS

| Overall data
Molecular analysis of our series of patients started 20 years ago.
Until year 2012, patients were analyzed by Sanger sequencing of the exons of the following genes: TYR, OCA2, TYRP1, SLC45A2, SLC24A5, GPR143, and HPS1. Since 2013, targeted next-generation sequencing (NGS) of all nineteen albinism genes was implemented (Table 1) .
Patients from the 1997 to 2012 periods in whom no mutation was found by Sanger sequencing were reanalyzed by NGS of the nineteen genes, so that a comprehensive analysis was achieved for all patients. A search for intragenic rearrangements (deletions, duplications) was performed by high-resolution array-CGH (comparative genomic hybridization) in all cases where either a single heterozygous variant was identified, therefore looking for a second variant, or when a homozygous variant was found, in order to exclude the existence of a deletion or duplication event. The common OCA2 exon 7 deletion was identified by either specific PCR assay, array-CGH, or NGS. Pathogenicity of single nucleotide variants was evaluated using bioinformatics tools Cartagenia (Agilent Technologies) and Alamut (Interactive BioSoftware, Rouen, France) (see Section 4). Parental DNA, when available, was used to confirm the segregation of the pathogenic variants.
Our flowchart for the molecular analysis of patients with albinism is presented in Figure S1 .
A total of 990 index patients were analyzed (other family members were not taken into consideration in the present study). A molecular diagnosis was achieved for 716 patients (72.32%): 300 (41.8%) OCA1; 200 (27.9%) OCA2; 15 (2.1%) OCA3; 75 (10.5%) OCA4; 22 (3.1%) OCA6; 3 (0.4%) OCA7; 50 (7%) OA1; 4 (0.6%) FHONDA; 17 (2.4%) HPS1; 0 (0%) HPS2; 2 (0.3%) HPS3; 2 (0.3%) HPS4; 10 (1.4%) HPS5; 12 (1.7%) HPS6; 1 (0.1%) HPS7; 2 (0.3%) HPS8; 0 (0%) HPS9; 0 (0%) HPS10, 2 (0.3%) CHS (Figure 1 ). 12.12% of the patients harbored only one heterozygous mutation, and 15.56% had no mutation in any of the 19 genes.
The genotypes of the patients with an established diagnosis are presented gene by gene in Tables S1-S17. A total of 243 novel pathogenic variants (so far neither published nor reported in variants databases) were identified (indicated in bold in the tables). Table S18 includes for each variant the number of patients, the number of occurrences, and the number of homozygotes.
While most variants were either private or present in only few patients, some were more common. These are for TYR: c.1118C>A/p. We identified 28 new intragenic deletions, including 4 in TYR, 7 in OCA2, 6 in SLC45A2, and 5 in GPR143. We describe the first deletions in the following genes: SLC24A5 (one deletion), SLC38A8 (two deletions), HPS1 (one deletion), HPS5 (one deletion), HPS6 (one deletion).
Overall, intragenic rearrangements were found in 110 patients (Table   S19 ) and represented 10.8% of all pathogenic alleles. As already reported (Morice-Picard, Lasseaux, Cailley et al., 2014) , the OCA2 gene is particularly prone to rearrangements, and 78 patients had a rearrangement of this gene, including the common exon 7 deletion (54 patients; 29 homozygotes).
| OCA1
OCA1, the most frequent form of the disease, represented 41.8% of the resolved cases (n = 300). 54 new variants, including four new intragenic deletions were identified (Tables S1 and S2) . c.575C>A/p.Ser192Tyr is another common TYR variant thought to have an additive effect when present in cis to c.1205G>A/p.Arg402Gln (Jagirdar et al., 2014; Norman et al., 2017) . From data in Table S2 , it can be counted that 21.9% of the alleles (61/278; 139 patients) have these variants in cis, a number much higher than the estimated frequency in the general population (1.1%-1.9%; Jagirdar et al., 2014; Norman et al., 2017 (Table S3) , also from New Caledonia, was homozygote for variant c.1045-9T>G/p.?. These three variants were not identified in any other patient from our series and were not described in the literature and seem therefore to be specific to New Caledonians.
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A total of 16 patients were compound heterozygotes for the OCA2 c.1256G>A/p.Arg419Gln variant and another OCA2 variant of known pathogenicity. OCA2 c.1256G>A/p.Arg419Gln is a common variant of undetermined pathogenicity (Hutton & Spritz, 2008; Preising, Forster, Gonser, & Lorenz, 2011) . These patients were therefore considered as not molecularly resolved.
| OCA3 and 4
OCA3 is a one of the rarest forms of oculocutaneous albinism (2.1%).
We identified 15 new pathogenic variants in the causative gene TYRP1 (Table S4 ).
10.4% of patients in our series were diagnosed with OCA4, and we identified 39 new SLC45A2 variants (Table S5 ).
| OCA6
A total of 22 patients were molecularly diagnosed with OCA6; 12 were homozygotes for a pathogenic variant, in accordance with a known or suspected consanguinity. Phenotypic features are presented in Table   S20 . They confirm our previous observation (Morice-Picard, Lasseaux, Plaisant et al., 2014) that OCA6 patients have typical ocular albinism, but variable cutaneous phenotypes, with a generally pale skin, a hair color ranging from white to brown, and a tendency to tan in nine of 14 patients in whom this feature was documented. Three patients from
French Guiana (SLC24A5-P11, SLC24A5-P12, SLC24A5-P20, Table   S6 ) were already reported (Bertolotti et al., 2016) .
Patient SLC24A5-P13 had Crohn's disease-like bloody diarrhea, and patient SLC24A5-P17 was described with frequent epistaxis, discrete respiratory obstructive syndrome with moderate thoracic distension syndrome without blood oxygenation anomaly but did not present with any clotting biological anomaly or immunological deficit (Table S20 ). These symptoms are partially reminiscent of those found in Hermansky-Pudlak syndrome. It has been suggested that protein SLC24A5 may be involved in the maturation of melanosomes or in the production of pigment in mature melanosomes and that BLOC-1 and BLOC-2, involved in Hermansky-Pudlak syndrome (HPS), could mediate the melanosomal targeting of SLC24A5, as it does for other melanogenic proteins such as TYR, TYRP1, OCA2, and ATP7A (Wei & Li, 2013) . This may explain why some OCA6 patients present with HPS-like symptoms. However, no other OCA6 patients have been described so far with such features, which may be present by chance in the two patients reported here.
| OCA7
OCA7 was first described in patients from the Faroe Islands and in one patient from Lithuania (Grønskov et al., 2013) Leu30Pro and c.163A>T/p.Asn55Tyr. All three patients had a pale skin and light brown hair, 2/3 had a tendency to tan, and 2/3 had bluish eyes (one was not documented). Ophthalmological features were typical, with a nystagmus in 3/3, foveal hypoplasia in 2/2 (one not documented), reduced visual acuity in 2/2 (one not documented), photophobia in 2/2 (one not documented), and iris transillumination in 2/2 (one not documented, but described with retinal hypopigmentation). This overall compared well with the phenotypic features previously described in OCA7 patients (Table S20) .
| OA1
Fifty male patients had a pathogenic variant in GPR143 (Table S8) .
Thirty-two new variants were identified. All OA1 patients had a clinical phenotype of ocular albinism. Pedigree analysis showed typical X-linked segregation. As discussed elsewhere in this article, clinical forms of ocular albinism can be due to variants in other genes (in particular TYR, SLC38A8, HPS genes).
| FHONDA
Mutations of the SLC38A8 gene were recently described in FHONDA (foveal hypoplasia, optic nerve decussation defects, and anterior segment dysgenesis) (Poulter et al., 2013) . SLC38A8 mutations were also described in Israeli families of Jewish Indian (Mumbai region) ancestry with foveal hypoplasia and nystagmus (Perez et al., 2014) . We identified four patients with pathogenic variants of this gene (Table S9) .
One variant (c.697G>A p.Glu233Lys) already described in an Indian family (Family 6 in Poulter et al., 2013) was found in a French patient (SLC38A8-P3). The other variants identified (four missense, one frameshift, and two intragenic deletions) were novel.
The patients' phenotypes (Table S20 ) were in accordance with that described in the initial report by Poulter et al., that is, absence of pigmentation defect, foveal hypoplasia, and reduction in visual acuity. Iris transillumination, not reported in former publications, was observed in two of our patients (SLC38A8-P1 and SLC38A8-P4).
| Hermansky-Pudlak syndrome
Hermansky-Pudlak syndrome associates oculocutaneous albinism and prolonged bleeding time, easy bruising, absence of platelet dense bodies and altered platelet aggregation test, and in some subtypes of the disease granulomatous colitis and interstitial pulmonary fibrosis.
There are 10 HPS subtypes (Table 1) . We identified 17 patients with HPS1, 2 with HPS3, 2 with HPS4, 10 with HPS5, 12 with HPS6, 1 with HPS7, and 2 with HPS8 (Tables S10-S16). Patients with HPS1 and 4
presented with severe forms of the disease (high degree of oculocutaneous depigmentation, severe outcome including granulomatous colitis, and interstitial pulmonary fibrosis). All patients with HPS3, 5, or 6 presented with rather mild symptoms, so that some were initially reported with clinical ocular albinism, as reported by us for HPS5 (Michaud et al., 2017) . HPS8 is one of the rarest forms of the disease (only two families described in the literature) in which patients present mild hypopigmentation, moderate visual defects, and slight platelet defects.
When HPS is molecularly diagnosed, performing a platelet aggregation and/or secretion tests is recommended to confirm the diagnosis.
| Chediak-Higashi syndrome
Chediak-Higashi syndrome is due to mutations in the LYST gene and is clinically characterized by anemia, thrombocytopenia, leukopenia, giant inclusion bodies in most granulated cells, severe susceptibility to infections at a very early age, neurodegeneration with tremor, abnormal gait, seizures, and progressive intellectual decline. We identified (Table S17) 
| Benefits and limits of targeted nextgeneration sequencing
Next-generation sequencing technology constitutes a valuable progress for the analysis of patients, allowing the analysis of all 19 known albinism-related genes in one experiment, with a coverage as high as 98.7% of all exons. Only 13 exons must be analyzed separately by Sanger sequencing to achieve completion. NGS speeds up patients' analysis tremendously, renders possible the diagnosis of the rarest forms of the disease, including Hermansky-Pudlak and ChediakHigashi syndromes, and allowed us to identify mutations which had been missed by Sanger sequencing due essentially to allele dropout.
Therefore, NGS analysis should now become the gold standard for this condition.
Next-generation sequencing data must, however, be analyzed with caution as illustrated by the following examples: (i) some exons are not, or only poorly, covered by the panel, and must therefore be Sanger sequenced; (ii) some variants are difficult to visualize as was the case for two small deletions (c.20_29del/p.Gln7Argfs*61 and c.32_33delGA/p.Arg11Lysfs*32), which were located next to one another in exon 1 of the SLC24A5 gene (SLC24A5-P15, Table S6 ). Close scrutiny of the BAM files was necessary to accurately characterize the two deletions, especially because one of them was present on only two reads. These variants were thereafter confirmed by parental DNA analysis; (iii) patient OCA2-P154 (Table S3) The NGS technique allowed the detection of copy number variants (CNVs) based on a comparison of sequence read depth using an inhouse plug-in we specifically developed. In our experience, virtually all deletion and duplication events can be identified by NGS, and then confirmed by a second technique (array-CGH or quantitative PCR), with the exception of purely intronic rearrangements, since the panel covers only the exons. In particular, NGS data analysis was instrumental in visualizing a 156-bp deletion in TYR exon 1 that was in trans of an exon 1 variant (c.307T>C/p.Cys103Arg) (TYR-P152, Table S1 ). This variant initially appeared to be homozygous, until analysis using the CNV detection plug-in showed that the patient was compound heterozygote for c.307T>C/p.Cys103Arg and the 156-bp deletion. This deletion was confirmed by high-resolution array-CGH.
| DISCUSSION
In the present study, we analyzed 990 index patients and established a molecular diagnosis in 716 (72.32%). A large number of new variants were identified; 10.8% of the pathogenic variants were intragenic rearrangements, which underscore the importance of systematically looking for these variants for diagnostic purposes.
The most frequent form of albinism is OCA1 (41.8% of cases), followed by OCA2 (27.9%), OCA4 (10.5%), OA1 (7%), OCA6 (3.1%), and OCA3 (2.1%). Notably about half (46.3%) of OCA1 patients are compound heterozygotes for a deleterious variant and the hypomorphic variant c.1205G>A/p.Arg402Gln. We present strong arguments indicating that this variant must be considered as pathogenic and leads to genuine mild forms of albinism.
The use of NGS to simultaneously sequence all 19 genes constituted a major progress since it allowed to diagnose the rarest forms of non-syndromic (OCA7 and FHONDA) and syndromic (HPS1-10 and CHS1) albinism, an important issue for patients with syndromic albinism who require a specific clinical follow-up.
Genotype-phenotype correlations are almost absent in patients with albinism. In particular, patients clinically diagnosed with "ocular albinism" may eventually either have OA1 (males), be compound heterozygotes for the TYR c.1205G>A/p.Arg402Gln hypomorphic variant, have FHONDA, or have a mild HPS form, particularly HPS3, 5, and 6 (see Michaud et al., 2017) . Without this comprehensive molecular analysis, some would therefore be left without a proper diagnosis of HPS.
In addition, simultaneous testing of all 19 albinism genes provided the unique opportunity to observe the existence of two forms of albinism, namely OCA3 and OA1, in one patient (patient TYRP1-P8/ GPR143-P19, Tables S4 and S8) . Although rare (no other such case was detected in our series), these situations must be uncovered since they impact genetic counseling.
Intragenic rearrangements (essentially deletions) represent as many as 10.8% of all pathogenic alleles in our series of patients and must therefore be systematically searched for. A specific plug-in allowed us to identify most of these rearrangements in the NGS data.
Our high-resolution CGH array covers the whole of the 19 genes (exons, introns, flanking regions) and stands as a unique tool to detect rearrangements in intronic or gene flanking sequences, which are not covered by the NGS panel (e.g., the complex OCA2 rearrangement, patients OCA2-P104 and OCA2-P59, Table S3 Wutz et al., 2002) and atypical PAX6-related phenotypes (Hood, Kerr, Smaoui, & Iannaccone, 2015; Thomas, Maconachie, Sheth, McLean, & Gottlob, 2017) . Atypical presentations of the various forms of congenital stationary night blindness may also present a clinical overlap with ocular forms of albinism.
Secondly, pathogenic variants may be located in the introns or in flanking sequences important for the regulation of gene expression (e.g., Regales, Giraldo, García-Díaz, Lavado, & Montoliu, 2003) , which
are not routinely sequenced in clinical laboratories. As a pilot study, we sequenced the entirety of the TYR, OCA2, TYRP1, and SLC45A2 genes (OCA1-4) in 16 patients heterozygote for a pathogenic variant in one of these genes. While all known heterozygous variants were successfully identified, no intronic variant susceptible to alter RNA splicing was identified using the bioinformatics tools developed by Liquori et al. (2016) . One insertion event was observed in the promoter region of the TYR gene. Functional studies, however, showed that this insertion did not significantly alter TYR expression (data not shown). No other variant was identified in the flanking sequences of the OCA1-4 genes. We believe that exploration of the non-exonic sequences of the albinism genes should be pursued.
Finally, it is likely that additional genes are involved in albinism.
These genes may be searched for by whole-exome or whole-genome sequencing strategies.
Albinism stands out as a group of disorders, which are heterogeneous at both the clinical and genetic levels and among which no clear phenotype/genotype correlation can be established. There is such a high level of phenotypic overlap between the oculocutaneous, the ocular, and even the syndromic forms of the disease that the diagnosis relies essentially on molecular genetics studies. As already stated (Montoliu & Kelsh, 2014) , pathogenic variants in albinism-associated genes might not necessarily display pigment alterations, and the visual alterations should constitute the common and defining trait for this group of diseases. Importantly, the information that patients with albinism may not have pigment alterations must be widely brought to the knowledge of medical students and practitioners. This will contribute to a better diagnosis of albinism, a condition that is still largely overlooked, and will avoid that patients are left without a proper diagnosis, which can have dramatic consequences especially in the case of a syndromic form.
| METHODS
| Patients
Patients, mainly from France, originated from different countries 
| DNA extraction
DNA was extracted from peripheral blood leukocytes either using an automated procedure (Tecan EVO-ReliaPrep, Promega) or manually (Wizard ® Genomic DNA Purification Kit; Promega) or from saliva (Oragen PrepIT DNA kit; Genotek). Mutations found by NGS were confirmed by Sanger sequencing. 
| Search for point mutations
| Bioinformatics analysis of variants
| Search for CNVs in NGS data
Intragenic rearrangements were visualized in NGS data using an inhouse plug-in based on NGS read depth. The strategy used a mathematical model to highlight regions with abnormal depth compared to the overall mean depth of all other patients on the same NGS run (Zhao, Wang, Wang, Jia, & Zhao, 2013 ).
| Array-CGH
Gene rearrangements (deletions, duplications) in all 19 albinism genes were searched for by high-resolution array-CGH (comparative genomic hybridization) according to an array design and procedure already described (Morice-Picard, Lasseaux, François et al., 2014). Gene rearrangements were validated by quantitative multiplex fluorescent PCR (Stef et al., 2007) .
